A combination phase II study of paclitaxel and gemcitabine for recurrent or relapsed non-small cell lung cancer previously treated with platinum or docetaxel-based regime
Phase 2
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-C000000219
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with lesions that can not judged for response by only chemotherapy. Patients previously treated with chemoradiotherapy are not allowed to be enrolled. 2) Active infectious disease and complications that affect the trial. 3) Apparent interstitial pneumonitis or fibrosis on chest X ray. 4) Symptomatic brain metastases. 5) Patients requiring pleural/ pericardial drainage. 6) Previous chemotherapy with gemcitabine or paclitaxel. 7) Allergy for a polyoxyethylene castor oil or a hardening castor oil component drug. 8) Woman who has a possibility of pregnancy. 9) Interval less than 30days from the last day of a previous treatment. 10) Other patients unsuitable for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method